Equities Analysts Offer Predictions for TCR2 Therapeutics Inc.’s FY2022 Earnings (NASDAQ:TCRR)

TCR2 Therapeutics Inc. (NASDAQ:TCRRGet Rating) – Analysts at HC Wainwright upped their FY2022 EPS estimates for TCR2 Therapeutics in a research note issued on Monday, November 21st. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($3.19) for the year, up from their prior forecast of ($3.29). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for TCR2 Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for TCR2 Therapeutics’ Q4 2022 earnings at ($0.82) EPS.

TCRR has been the topic of a number of other research reports. Piper Sandler cut their price target on TCR2 Therapeutics from $16.00 to $8.00 in a report on Tuesday, November 8th. Truist Financial cut their price target on TCR2 Therapeutics to $18.00 in a report on Tuesday, August 23rd. Finally, Roth Capital reaffirmed a “buy” rating on shares of TCR2 Therapeutics in a report on Monday, August 8th.

TCR2 Therapeutics Trading Up 0.8 %

TCRR opened at $1.27 on Wednesday. The business’s 50 day moving average is $1.62 and its 200-day moving average is $2.41. The stock has a market cap of $49.09 million, a PE ratio of -0.41 and a beta of 1.77. TCR2 Therapeutics has a twelve month low of $1.23 and a twelve month high of $5.65.

Institutional Investors Weigh In On TCR2 Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP grew its position in TCR2 Therapeutics by 113.2% in the first quarter. GSA Capital Partners LLP now owns 158,593 shares of the company’s stock worth $438,000 after buying an additional 84,191 shares during the last quarter. Marquette Asset Management LLC grew its position in TCR2 Therapeutics by 20.7% in the second quarter. Marquette Asset Management LLC now owns 40,163 shares of the company’s stock worth $116,000 after buying an additional 6,901 shares during the last quarter. Acadian Asset Management LLC grew its position in TCR2 Therapeutics by 3,250.7% in the first quarter. Acadian Asset Management LLC now owns 479,518 shares of the company’s stock worth $1,322,000 after buying an additional 465,207 shares during the last quarter. Sawtooth Solutions LLC acquired a new position in TCR2 Therapeutics in the first quarter worth approximately $87,000. Finally, Nan Fung Group Holdings Ltd acquired a new position in TCR2 Therapeutics in the first quarter worth approximately $53,000. Institutional investors own 64.56% of the company’s stock.

TCR2 Therapeutics Company Profile

(Get Rating)

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

See Also

Earnings History and Estimates for TCR2 Therapeutics (NASDAQ:TCRR)

Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.